NeuroNascent Continues to See Positive Clinical Data with Alzheimer’s Therapy

Published on : Published by : Alex Keown

Although Aduhelm has not panned out, there are still a number of medications in clinical development for this devastating form of dementia, including Maryland’s NeuroNascent, Inc., which is developing a new chemical entity that the company hopes will be able to reverse some or all of the dreaded disease deficits, through the production of new neurons. The Rockville-based company’s lead drug candidate, NNI-362 is being developed as a potential Alzheimer’s therapy that actually preclinically demonstrated the ability to produce new neurons.

NeuroNascent Takes New Path for Alzheimer’s Treatment

Published on : Published by : Alex Keown

Alzheimer’s disease has been one of the toughest disorders for drugmakers to tackle, with multiple trial failures year after year. Companies have exhausted resources as they examined different pathways in what have mostly been futile attempts to develop a therapeutic to halt or delay the onset of this devastating neurodegenerative disease.

Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders

Published on : Published by : Sharlene Brown, PhD

Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders Several Maryland Biotech Firms Are Blazing New Trails in Gene Therapy, Drugs and Diagnostics for Neurological [….]